AS/Spondyloarthritis
Janet Pope Janetbirdope
4 years 3 months ago
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 3 months ago
What can define +MRI for active spine lesions in axSpA?
*⃣ BME in >/=4 vertebral corners (VCs)
*⃣BME in >/= 3 VCs if w/ at least 1 non-corner inflamm lesion
*⃣BME in >/=1 VC if w/ at least 2 VC fat lesions
Such cut-offs achieve >/= 95% specificity
OP0252. #EULAR2021 @Rheumnow https://t.co/5CTan2BgLK
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 3 months ago
Phenotypes in axPsA per Dr. Gladman:
⭐️15% develop axial dz at 10y: # of radiographic damaged joints, periostitis, & ⬆️ESR predictive. HLA-B27 no longer predictive
⭐️Buttock pain & IBD more common in axial dz
⭐️M had more axial dz + radiographic damage
#EULAR2021. @Rheumnow
Richard Conway RichardPAConway
4 years 3 months ago
Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
1. EULAR2021 - Day2a
2. EULAR2021 - Day2b
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
The second day of EULAR 2021 took a big leap in online content. #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty.
Dr. John Cush RheumNow
4 years 3 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlights from Day 2.
Dr. Rachel Tate uptoTate
4 years 3 months ago
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h
Eric Dein ejdein1
4 years 3 months ago
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.
Dr. John Cush RheumNow
4 years 3 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 3 months ago
Do you increase spacing of TNF-i administration in your patients with axSpA with sustained low disease activity for one year? OP0138 results showed similar relapse rates in those with increased spacing intervals and those on standard dosing regimen. #EULAR2021 @RheumNowNews
Poster Hall